RxDoctor Payments Data

Raymond Ketcham

Pain Medicine · Scottsdale, AZNPI 1285108514

Payments from drug & device makers

$3,670in general payments, 2019–2025

Across 215 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$778
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$749
  • AbbVie$460
  • Hikma Pharmaceuticals USA$316
  • Valinor Pharma, LLC$314
  • Protega Pharmaceutials Inc$253
  • plus $801 from 14 others

What the payments were for

  • Food & beverage$3,44694%
  • Education$2246%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,670 in reported general payments places this provider in the 45th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$402,133
Medicare patients
170
Services billed
3,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl81$78,520
OxycontinOxycodone Hcl135$65,793
Xtampza ErOxycodone Myristate113$53,469
Oxycodone Hcl2,225$51,402
MovantikNaloxegol Oxalate55$27,442
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl79$16,550
UbrelvyUbrogepant12$15,497
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen300$10,377
Naloxone Hcl161$9,325
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen201$9,061
Fentanyl68$8,103
Morphine Sulfate160$7,926
Morphine Sulfate ErMorphine Sulfate361$7,553
Buprenorphine30$7,204
ButransBuprenorphine13$7,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$778$131,989194 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate, Buprenorphine, Buprenorphine Hcl$316$32,829302 claims
Redhill Biopharma Inc.Movantik$34$27,44255 claims
AbbVieUbrelvy$460$15,49712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →